Australia's most trusted source of pharma news
Tuesday, 21 April 2015
Lost Your Access?
Patients misled on new drugs says Hill
Alleging patients are consistently misled about drugs presented to the PBAC, outgoing chair Susan Hill has made a strong call for much less confidentiality around submissions.
Health reveals 'new' PBAC approach
In what officials described as a 'new approach', the Health Department trialled a rolling submission procedure for MSD's
Companies quiet on latest price cuts
Companies which have bDMARDs listed on the PBS for psoriatic arthritis are facing possible price cuts, though many are remaining mum about it.
Parallel processing failing patients
Pharma companies are being 'disincentivised' from using parallel processing system for oncology submissions because of its low success rate MA has said.
Uncertainty plagues access path: MSD
MSD's frustration with TGA and PBAC processes was clear at the Senate inquiry into the availability of new, innovative and specialist cancer drugs in Australia.
Market exits could hit cancer: GMiA
Continuing exits from the cancer generics market present a risk to supply says the GMiA in its submission to the Senate inquiry on cancer drug availability.
Coversyl win is costly for generics
Generic companies may have succeeded in invalidating Servier's
patent but could be up for close to $1m in costs.
Another company tightens free access
Roche, like Novartis, is phasing in a tighter policy for subsidised access to its medicines, citing the "increasingly challenging and uncertain" funding environment.
PBAC sets out early access demands
The PBAC is calling for real-time monitoring of clinical outcomes for new drugs and for reimbursement submissions to be opened to patients and clinicians.
Health hints at PBS de-listing policy
The Health Dept submission to the Senate cancer medicines inquiry, finally made public, shows strong commitment to keeping downward pressure on prices and hints at a PBS 'de-listing' policy.
Another generic company quits Aust
Aurobindo sells its Australian generics portfolio to Eris Pharmaceuticals Australia, which says it is now set to become a significant generics player.
IMS dragged into News v Guild stoush
News Limited's attacks on pharmacy have spilled over to affect IMS Health which has been forced to defend its script-based market research services.
Heart effects cloud gliptins' future
An FDA review of new data on AZ's
due to come to a head overnight could affect the future of the entire DPP4 class of diabetes drugs.
CW's trademark was 'terminally ill'
In calling for the cancellation of Chemist Warehouse's trademark after a dispute with a rival, the Federal Court has described it as 'terminally ill'.
Eylea's lead on Lucentis will grow
A state by state analysis of PBS benefits shows that the AMD market battle is swinging very much in Bayer's favour.
MSD 'working' on PBS for Keytruda
As it announces the official TGA registration of melanoma treatment
, MSD says it is continuing to work with the government on PBS listing.
MSD facing $26m diabetes challenge
MSD has seen the first rival brands registered against its top-selling gliptin,
while GSK has won approval of an HSA-free version of
Would pharmacy deregulation make a difference?
What if the government accepts the Harper review recommendation and scraps pharmacy location and ownership rules? Would it be so bad?
Exclusive Q&A with new Bayer boss Nelson Ambrogio
Nelson Ambrogio became Bayer's new country representative for Australia at the start of this month. In this exclusive Q&A he talks to
Pharma in Focus
about the core issues for his company and the industry, and tells some of his own story.
Antidote in view for remaining NOACs
An antidote to novel oral anticoagulants
is expected to be filed by year end while Shire has won a priority FDA review for dry eye treatment lifitegrast.
Events & Conferences
© 2003 - 2015 Lush Media
Pharma in Focus
Jolly Good Design